Nivoi seruma CA19-9 i CEA, nivoa seruma CAT, GSH, oksidovanog glutationa, 8-dihidro-2′-deoksigvanozina i F2-izoprostana kod pacijenata sa kolorektalnim karcinomom tretiranim Lactobacillusom: Randomizovano dvostruko slepo kontrolisano ispitivanje

  • Shiru Chen Department of Digestive Minimally Invasive Diagnosis and Treatment, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150000, China.
  • Weili Ning 2. Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150000, China
  • Jiye Zhang 1. Department of Digestive Minimally Invasive Diagnosis and Treatment, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150000, China
  • Zhenting Wu Department of Digestive Minimally Invasive Diagnosis and Treatment, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150000, China.
  • Hang Zhou 1. Department of Digestive Minimally Invasive Diagnosis and Treatment, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150000, China.
  • Ying Liu First Affiliated Hospital of Heilongjiang University of Chinese Medicine in Harbin
DOI: https://doi.org/10.5937/jomb0-56528
Ključne reči: Lactobacillus, kolorektalni karcinom, oksidativni stres, p38 MAPK, JNK, NRF2

Sažetak


Pozadina: Oksidativni stres (OS) ima ključnu ulogu u progresiji kolorektalnog karcinoma (CRC). Predloženo je da Lactobacillus može biti potencijalni modulator OS-a. Ovo randomizovano kontrolisano ispitivanje imalo je za cilj da proceni efekte suplementacije Lactobacillusom na markere OS-a i povezane signalne puteve kod pacijenata sa CRC-om nakon operacije.

Metode: Ukupno 76 pacijenata sa CRC-om bilo je uključeno i randomizovano u dve grupe: studijsku grupu (n=39), koja je primala suplementaciju Lactobacillusom, i kontrolnu grupu (n=37), koja je primala placebo. Intervencija je trajala šest meseci nakon operacije. Mereni su nivoi seruma katalaze (CAT), glutationa (GSH), oksidovanog glutationa (GSSG), 8-oxo-7,8-dihidro-2′-deoksigvanozina (8-oxodG) i F2-izoprostana (F2-IsoPs). Pored toga, signalni putevi NRF2/KEAP1, p38 MAPK i JNK procenjeni su putem western blot analize.

Rezultati: Nakon suplementacije Lactobacillusom, nivoi serumskog CEA su se značajno smanjili, dok su nivoi CA19-9 ostali nepromenjeni. Analiza markera OS-a pokazala je povećane nivoe CAT, GSH i F2-IsoPs, kao i smanjene nivoe GSSG i 8-oxodG u studijskoj grupi u poređenju sa kontrolnom grupom. Rezultati western blot analize pokazali su da su nivoi proteina NRF2, ASK1, MKK3, p-p38 i MKK4 značajno smanjeni nakon intervencije Lactobacillusom, dok su nivoi KEAP1 i p-JNK ostali nepromenjeni.

Zaključci: Oralna administracija Lactobacillusa tokom šest meseci smanjila je nivoe markera OS-a i inhibirala signalne puteve NRF2/KEAP1, p38 MAPK i JNK kod pacijenata sa CRC-om nakon operacije. Ovi nalazi sugerišu da Lactobacillus može doprineti upravljanju CRC-om modulacijom oksidativnog stresa.

Objavljeno
2025/05/07
Broj časopisa
Vol. 44 Br. 7 (2025): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2025 Shiru Chen, Weili Ning, Jiye Zhang, Zhenting Wu, Hang Zhou, Ying Liu

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.